Internal Medicine, Gastroenterology · Brooklyn, NY
NPI
1093866386
Since 2007
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1664 E 14th St Ste 302
Brooklyn, NY, 11229
Phone (718) 382-0500
Groups this clinician bills Medicare through
Medicare paid, 2024
$268K
5,451 services
Medicare patients, 2024
552
Average age 79
Drug cost, 2024
$1.7M
4,950 prescriptions
Company payments, 2025
$979
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Inna Gordin was code 95004 (test - miscellaneous), 2,104 times for 33 patients. In total Inna Gordin billed 5,451 services in 36 codes, and Medicare paid $268K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 2,104 | 33 | $3.59 | $7,555 |
| 99442 Telephone Services | Office | 552 | 366 | $79.33 | $44K |
| 88305 Surgical Pathology Examination | Office | 510 | 139 | $31.26 | $16K |
| 88313 Surgical Pathology Examination | Office | 323 | 107 | $10.27 | $3,317 |
| 99214 Office E&M - Established | Office | 310 | 247 | $114.49 | $35K |
| 88312 Surgical Pathology Examination | Office | 303 | 105 | $22.33 | $6,765 |
| 88342 Immunohistochemistry | Office | 259 | 97 | $29.27 | $7,580 |
| 99443 Telephone Services | Office | 231 | 168 | $114.81 | $27K |
| 99213 Office E&M - Established | Office | 230 | 166 | $77.24 | $18K |
| 99204 Office E&M - New | Office | 134 | 134 | $146.77 | $20K |
| 43239 Upper GI Endoscopy | Office | 105 | 105 | $336.87 | $35K |
| 36415 Venipuncture Blood Collection | Office | 86 | 74 | $8.65 | $744 |
| 76981 Ultrasound - Nonspecific | Office | 75 | 64 | $96.19 | $7,214 |
| 45380 Lower GI Endoscopy - Other | Office | 48 | 48 | $290.16 | $14K |
| 82272 Immunoassay | Office | 43 | 43 | $4.15 | $178 |
By year: 2022 $301K for 3,705 services; 2023 $289K for 5,368 services; 2024 $268K for 5,451 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 510 | 139 | $31.26 | $16K |
| 88313 Surgical Pathology Examination | 323 | 107 | $10.27 | $3,317 |
| 88312 Surgical Pathology Examination | 303 | 105 | $22.33 | $6,765 |
| 88342 Immunohistochemistry | 259 | 97 | $29.27 | $7,580 |
| 36415 Venipuncture Blood Collection | 86 | 74 | $8.65 | $744 |
| 82272 Immunoassay | 43 | 43 | $4.15 | $178 |
Medicare prescription drug claims, 2024
In 2024, the drug Inna Gordin prescribed most often to Medicare patients was Linzess (Linaclotide), with 646 prescriptions and refills. In total Inna Gordin wrote 4,950 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Linzess Linaclotide | 646 | 686 | 111 | $356K |
| Pantoprazole Sodium Generic | 376 | 426 | 113 | $1,906 |
| Zenpep Lipase/Protease/Amylase | 341 | 354 | 77 | $410K |
| Dexlansoprazole Dr Dexlansoprazole | 287 | 317 | 62 | $50K |
| Dexilant Dexlansoprazole | 283 | 285 | 36 | $87K |
| Famotidine Generic | 268 | 302 | 67 | $1,064 |
| Omeprazole Generic | 260 | 342 | 79 | $1,330 |
| Creon Lipase/Protease/Amylase | 126 | 131 | 40 | $111K |
| Nexium Esomeprazole Magnesium | 107 | 111 | 13 | $32K |
| Dicyclomine Hcl Generic | 84 | 84 | 45 | $1,192 |
| Vascepa Icosapent Ethyl | 81 | 88 | 14 | $30K |
| Mesalamine Generic | 80 | 82 | 13 | $13K |
| Ursodiol Generic | 74 | 74 | Under 11 | $3,290 |
| Lubiprostone Generic | 74 | 83 | 13 | $9,589 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 72 | 72 | 70 | $4,212 |
Brand drugs: - claims; generic drugs: 2,720 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Inna Gordin $979 ($979 in general payments such as food, travel and fees) from 11 companies. The largest payer was Madrigal Pharmaceuticals with $172.
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals MDGL | 5 | $172 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 8 | $172 |
| Abbvie Inc. ABBV | 8 | $164 |
| Aimmune Therapeutics, Inc. | 5 | $157 |
| Ardelyx, Inc. ARDX | 3 | $90.89 |
| Lilly USA, LLC LLY | 3 | $80.78 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 1 | $32.82 |
| Intra-Sana Laboratories | 1 | $32.22 |
| Gilead Sciences, Inc. GILD | 1 | $26.2 |
| Vivus LLC | 1 | $25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.